Navigation Links
Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.

CHICAGO and PHOENIX, Jan. 9 /PRNewswire/ -- Houlihan Smith & Co., Inc. acted as the exclusive advisor in arranging a non-control equity investment into Sottera, Inc. d/b/a NJOY, as announced by Charles Botchway, Group Managing Director and Vice Chairman of Houlihan Smith & Company, Inc. The transaction was led by Houlihan Smith Managing Director Reginald McGaugh. Terms were not disclosed.

"We appreciate the process management and financial advisory services provided by Reginald McGaugh and his team at Houlihan Smith & Company, Inc. related to this equity investment," said Jack Leadbeater, CEO of Sottera. "We look forward to continuing our capital-raising process with Mr. McGaugh and his team as we continue our international growth."

"This investment represents a significant opportunity for NJOY to achieve growth initiatives related to its revolutionary product," said McGaugh, who worked directly with NJOY to establish the equity investment. "The facility will be used to support the continued growth of NJOY based on recently signed distribution agreements in North America, South America, and Asia."

Based in Scottsdale, Arizona, Sottera has filed for patents to manufacture and distribute groundbreaking products and technology represented by the trademarked brand NJOY ( The name Sottera is derived from Soteria, the Greek god of preservation, redemption and salvation. These three words are the essence of the NJOY brand and products, which give tobacco users the opportunity to continue smoking with greater freedom, lower cost and more social acceptance. NJOY is currently being sold in all 50 states and in more than 25 foreign countries. NJOY is available online at for shipment around the globe, and is also available on affiliated websites and at retail locations across the U.S.

Miri Pharma, Inc. is a division of Canderm Pharma, Inc. Canderm Pharma, Inc. develops and sells cosmeceuticals, over-the-counter (OTC) skin care products, and dermatological items. Its product line includes ArtteSense, Betacaine, Cliniderm, Lipsorex, NeoStrata, Rosacure, and Ultraquin, as well as Condyline Topical Solution, Dermagran II, Epi-Derm, and UltraMOP. The firm also sells Ayria, a skin care line sold exclusively through dermatologists, and distributes Radiesse, produced by BioForm Medical, a trendy injectable filler alternative to facelifts.

Houlihan Smith & Company, Inc. ("Houlihan") is a specialized investment banking firm that provides advisory, financing, and valuation services to public and private businesses. Houlihan is a registered broker-dealer and FINRA/SIPC Member.

Houlihan understands the time sensitivity of corporate finance, and responds quickly and tenaciously to opportunities. The Houlihan approach creates corporate finance transactions in which business owners and investors mutually benefit. We have the knowledge, experience and relationships to match buyers and sellers, as well as to match the appropriate financing and capitalization structure to each unique client situation. The Houlihan name is synonymous with professional financial expertise. We provide cost-effective fairness and solvency opinions, as well as valuations for tax and financial reporting, to some of the largest NYSE/NASDAQ companies, as well as small, privately held businesses. (

     Rebecca Carriere

SOURCE Houlihan Smith & Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
2. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
3. AUDIO from Medialink and GlaxoSmithKline: FDA Approves Boostrix for Adults
4. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
5. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
6. GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
7. US District Court Enters Final Judgment in Favor of Smith & Nephew; Permanent Injunction Prohibits Arthrex Inc. From Selling Infringing Medical Devices
8. SpineSmith Partners Collaborates with University of Texas Biomedical Engineering Students to Develop Innovative Products
9. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
10. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
11. District Court Sides with Smith & Nephew; Rules that It will Issue Injunction that will Prohibit Arthrex Inc. from Selling Infringing Medical Devices
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
Breaking Biology News(10 mins):